Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LRAT | O95237 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13540662 | 0.85 | OGA (0.35) | MEN1LRATTRPV1TSHRALDH1A1 | |
| SCHEMBL21535992 | 0.85 | MAPK1 (0.34) | MAPK1CA1CA2CA9TSHR | |
| SCHEMBL25826964 | 0.85 | MAPK1 (0.34) | MAPK1CA1CA2CA9TSHR | |
| SCHEMBL25826968 | 0.85 | MAPK1 (0.34) | MAPK1CA1CA2CA9TSHR | |
| SCHEMBL20748418 | 0.83 | ALDH1A1 (0.32) | MAPK1CA1CA2CA9MEN1 | |
| SCHEMBL19529414 | 0.81 | L3MBTL1 (0.31) | MAPK1CA1CA2CA9 | |
| SCHEMBL22652618 | 0.81 | L3MBTL1 (0.34) | — | |
| SCHEMBL13207980 | 0.81 | LGALS1 (0.38) | TSHRALDH1A1LMNAHSD17B10THRB | |
| SCHEMBL9914095 | 0.81 | LGALS1 (0.38) | TSHRALDH1A1LMNAHSD17B10THRB | |
| SCHEMBL19221918 | 0.81 | LGALS1 (0.38) | TSHRALDH1A1LMNAHSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272766-A1 | APTAMER-MODIFIED POLYMERIC MATERIALS FOR FOR USE AS A FOAM IN A WOUND DRESSING | KCI Licensing, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-3009445-B1 | APTAMER-MODIFIED POLYMERIC MATERIALS FOR BINDING OF THERAPEUTIC FACTORS IN WOUNDS | KCI LICENSING INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048638-A1 | HEPARAN SULFATE INHIBITORS | HPSE, ENGASE, CSGALNACT1 | MAPK1 1818/4885CA1 2829/4885CA2 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.